Harbour BioMed and Kelun-Biotech announce that China’s National Medical Products Administration (NMPA) has approved an Investigational New Drug (IND) application for a candidate targeting asthma. The program is referred to by two names—HBM7575 and SKB575—depending on the parties’ naming conventions. The companies say the approved IND relates to the treatment of asthma and enables them to move forward with planned clinical development under China’s regulatory framework.
The announcement is distributed in a joint release dated July 15, 2026. Harbour BioMed, based in Cambridge, Massachusetts, and Kelun-Biotech, based in Chengdu, China, describe the collaboration as focused on developing antibody therapeutics, including in immunology. While both sources emphasize the NMPA IND approval as the key regulatory milestone, neither release provides detailed trial design, dosing, timelines, or efficacy results in the supplied text. The companies present the approval as a step toward initiating or continuing clinical evaluation of the asthma candidate in China.
